Page last updated: 2024-08-26

yttrium radioisotopes and Hematologic Malignancies

yttrium radioisotopes has been researched along with Hematologic Malignancies in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bodei, L; Chiti, A; Cremonesi, M; Ezziddin, S; Forrer, F; Hicks, RJ; Kidd, M; Luster, M; Modlin, IM	1
Camphausen, K; Carrasquillo, JA; Chakraborty, M; Gelbard, A; Hodge, JW; Mamede, M; Paik, CH; Schlom, J; Yu, S	1
Gopal, AK; Zhang, MM	1

Reviews

1 review(s) available for yttrium radioisotopes and Hematologic Malignancies

Article	Year
Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Seminars in hematology, 2008, Volume: 45, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, CD20; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Clinical Trials as Topic; Combined Modality Therapy; Forecasting; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukocyte Common Antigens; Myeloablative Agonists; Radioimmunotherapy; Rituximab; Sialic Acid Binding Ig-like Lectin 3; Survival Analysis; Transplantation Conditioning; Yttrium Radioisotopes	2008

Article

Year

Radioimmunotherapy-based conditioning regimens for stem cell transplantation.

Seminars in hematology, 2008, Volume: 45, Issue:2

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, CD20; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Clinical Trials as Topic; Combined Modality Therapy; Forecasting; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukocyte Common Antigens; Myeloablative Agonists; Radioimmunotherapy; Rituximab; Sialic Acid Binding Ig-like Lectin 3; Survival Analysis; Transplantation Conditioning; Yttrium Radioisotopes

2008

Other Studies

2 other study(ies) available for yttrium radioisotopes and Hematologic Malignancies

Article	Year
Myeloid neoplasms after chemotherapy and PRRT: myth and reality. Endocrine-related cancer, 2016, Volume: 23, Issue:8 Topics: Hematologic Neoplasms; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Peptide; Yttrium Radioisotopes	2016
Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer immunology, immunotherapy : CII, 2008, Volume: 57, Issue:8 Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Cancer Vaccines; Cell Line, Tumor; fas Receptor; Hematologic Neoplasms; Mice; Mice, Transgenic; Radioimmunotherapy; Sensitivity and Specificity; Tissue Distribution; Treatment Outcome; Up-Regulation; Yttrium Radioisotopes	2008

Article

Year

Myeloid neoplasms after chemotherapy and PRRT: myth and reality.

Endocrine-related cancer, 2016, Volume: 23, Issue:8

Topics: Hematologic Neoplasms; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Peptide; Yttrium Radioisotopes

2016

Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects.

Cancer immunology, immunotherapy : CII, 2008, Volume: 57, Issue:8

Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Cancer Vaccines; Cell Line, Tumor; fas Receptor; Hematologic Neoplasms; Mice; Mice, Transgenic; Radioimmunotherapy; Sensitivity and Specificity; Tissue Distribution; Treatment Outcome; Up-Regulation; Yttrium Radioisotopes

2008